UK's Oxford Cannabinoid gains on positive update from drug trial

Oxford Cannabinoid Technologies Holdings

25/09/2023 08:32

** Shares of Oxford Cannabinoid Technologies Holdings Plc
 OCTP.L  rise  5% to 1.0250p; stock among top pct gainers across
London
    ** Pharma firm developing prescription cannabinoid medicines
says final dose of its lead pharmaceutical drug compound,
OCT461201, successfully administered, as part of Phase I
clinical trial, with no adverse effects observed
    ** Co expects to report results of trial, conducted in the
UK using a single ascending dose protocol, by Oct. 16
    ** OCTP says trial's principal objective is to demonstrate
safety and tolerability of OCT461201, providing pivotal
information on its pharmacokinetic profile
    ** Stock at session high, taking YTD gains to ~23%

 (Reporting by Aby Jose Koilparambil in Bengaluru)
 ((abyjose.koilparambil@thomsonreuters.com))